Area of investment and support

Innovative medicines initiative

The Innovative Medicines Initiative aims to build a more collaborative ecosystem for pharmaceutical research and development in Europe and to speed up the development of more effective and safer medicines for patients.

• Partners involved: Medical Research Council (MRC)

The scope and what we're doing

The Innovative Medicines Initiative (IMI) is a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

IMI’s overall goal is to build a more collaborative ecosystem for pharmaceutical research and development in Europe and to speed up the development of more effective and safer medicines for patients.

The research funded under IMI addresses the IMI scientific research agenda. For 2014 to 2020 this focused on delivering the right prevention and treatment for the right patient at the right time through four main research areas:

• target validation and biomarker research (efficacy and safety)
• adoption of innovative clinical trial paradigms
• innovative medicines
• patient-tailored adherence programmes.

Opportunities, support and resources available

The Innovative Medicines Initiative (IMI) supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. Funding is distributed through peer-reviewed funding opportunities.

Find funding opportunities on the Innovative Medicines Initiative website.

Who to contact

MRC and Innovative Medicines Initiative

Email: international@mrc.ukri.org

Last updated: 13 September 2024